A Non-Conventional Platinum Drug against a Non-Small Cell Lung Cancer Line

Molecules. 2023 Feb 10;28(4):1698. doi: 10.3390/molecules28041698.

Abstract

A dinuclear Pt(II) complex with putrescine as bridging polyamine ligand ([Pt2Put2(NH3)4]Cl4) was synthesized and assessed as to its potential anticancer activity against a human non-small cell lung cancer line (A549), as well as towards non-cancer cells (BEAS-2B). This effect was evaluated through in vitro cytotoxicity assays (MTT and SRB) coupled to microFTIR and microRaman spectroscopies, the former delivering information on growth-inhibiting and cytotoxic abilities while the latter provided very specific information on the metabolic impact of the metal agent (at the sub-cellular level). Regarding cancer cells, a major impact of [Pt2Put2(NH3)4]Cl4 was evidenced on cellular proteins and lipids, as compared to DNA, particularly via the Amide I and Amide II signals. The effect of the chelate on non-malignant cells was lower than on malignant ones, evidencing a promising low toxicity towards healthy cells.

Keywords: A549 lung cancer; anticancer; microFTIR; microRaman; platinum complexes; polyamines.

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Carcinoma, Non-Small-Cell Lung*
  • Cell Line, Tumor
  • Humans
  • Lung Neoplasms*
  • Platinum / pharmacology

Substances

  • Platinum
  • Antineoplastic Agents